Colorectal

Can A Cancer Drug Originated In China Be A Success In The U.S.?

(Forbes) Sept 13, 2018 - While China has prospered in a variety of technologies over the last decade, one area where growth has been slow has been in innovative drug R&D.

read article

Better Understanding Of How Colon Cancer Develops And Progresses

(University of Luxembourg) Sept 11, 2018 - Researchers from the University of Luxembourg have discovered a molecular mechanism that is responsible for the spread of cancer cells in the body and the development of metastases in patients with colon cancer. Their findings could help to develop treatments that inhibit tumor growth.

read article

Study: More Than 14,000 Americans Die Each Year From This Preventable Cancer

(Forbes) Sept 10, 2018 - Not all medical tests justify the risks they pose. But there are some tests so safe and so necessary that it can be dangerous, even deadly, for patients not to participate. Screening for colon cancer is one example.

read article

Cross-Industry Collaboration of GNS Healthcare, Amgen and Alliance for Clinical Trials in Oncology to Leverage AI to Advance Understanding of Treatment Response in Metastatic Colorectal Cancer

(Markets Insider) Sept 6, 2018 - GNS Healthcare, a leading precision medicine company, announced a cross-industry partnership with Amgen and the Alliance for Clinical Trials in Oncology (Alliance) that will apply causal artificial intelligence (AI) and simulation to combined clinical trial data to identify factors that drive treatment response in patients with metastatic colorectal cancer (CRC).

read article

Boost For 'Made In China' Medicine As Chi-Med Wins Key Approval

(Reuters) Sept 5, 2018 - Hutchison China MediTech has won Chinese approval for a closely watched new cancer drug in a significant boost for “made in China” medicine. The London-listed company - which is known as Chi-Med and is collaborating with Eli Lilly on the drug - said on Wednesday that the National Medical Products Administration of China had approved Elunate or fruquintinib in colorectal cancer. The medicine is the first China-discovered and developed mainstream cancer drug to win unconditional approval following a randomized clinical trial. Shares in Chi-Med rose more than 4 percent on the news.

read article

Boost for 'Made In China' Medicine As Chi-Med Wins Key Approval

(Channel News Asia) Sept 5, 2018 - Hutchison China MediTech has won Chinese approval for a closely watched new cancer drug in a significant boost for "made in China" medicine.

read article

China Is Poised To Approve Its First Innovative Homegrown Drug For A Common Cancer. Next Stop? The U.S.

(STAT Plus) Sept 4, 2018 - China’s equivalent of the U.S. Food and Drug Administration is expected in the coming days to approve Chi-Med’s lead drug, known as fruquintinib, for patients with advanced colon cancer who have already tried two or more chemotherapies.

read article (paid subscription required)

A Model Based on Serial Liquid Biopsy Sampling May Predict Time to Progression in Patients With Colorectal Cancer

(AACR) Aug 30, 2018 - An evolutionary model utilizing serial blood samples from patients with advanced colorectal cancer treated with anti-EGFR therapies in a phase II trial could predict personalized waiting time for progression, according to results published in Cancer Discovery.

read press release

Exact Sciences and Pfizer Enter into U.S. Promotion Agreement for Cologuard®

(Markets Insider) Aug 22, 2018 - Exact Sciences Corp. and Pfizer Inc. today announced an agreement through 2021 to co-promote Cologuard, the first and only FDA-approved non-invasive stool DNA screening test for colorectal cancer. Pfizer will join Exact Sciences' sales representatives in reaching both physicians and health systems and will also actively participate in extending and deepening the Cologuard marketing campaign.

read article

Real-World Outcomes of Regorafenib for Metastatic Colorectal Cancer Consistent With Clinical Trials Despite Flexible Dosing

(Journal of Clinical Pathways) Aug 22, 2018 - Patients with metastatic colorectal cancer (mCRC) treated in the real-world setting experienced comparable survival benefits and safety outcomes compared with clinical trials, despite more than half of patients starting on a dose lower than the approved dose, according to a presentation at the ESMO World Congress on Gastrointestinal Cancer.

read article

AI Permits Diagnose-and-Leave Plan for Small Polyps

(MedPage Today) Aug 13, 2018 - Computer-aided diagnosis (CAD) in colonoscopy may provide real-time differentiation between neoplastic polyps requiring resection and non-neoplastic polyps that can safely be left in place, according to a Japanese study in Annals of Internal Medicine.

read article (free registration required)

From ‘Sea Of Mutations,’ Two Possible Cancer Links Rise To The Surface

(Princeton University) Aug 8, 2018 - By analyzing data from thousands of patients, Princeton researchers have identified genetic mutations that frequently occur in people with uterine cancer, colorectal cancer or skin cancer — an important step toward using genome sequences to better understand cancer and guide new treatments.

read article

Common Skin Cancer Can Signal Increased Risk Of Other Cancers

(Stanford Medicine) Aug 9, 2018 - People who develop abnormally frequent cases of a skin cancer known as basal cell carcinoma appear to be at significantly increased risk for the development of other cancers, including blood, breast, colon and prostate cancers, according to a new study from Stanford.

read press release

Genetic Mutations of Appendix Cancer Identified, May Impact Treatment

(UC San Diego) Aug 8, 2018 - Appendix cancer is currently treated like colon cancer, but significant differences may alter therapy choices.

read press release

Array BioPharma Receives FDA Breakthrough Therapy Designation for BRAFTOVI™ in Combination with MEKTOVI® and Cetuximab for BRAFV600E-mutant Metastatic Colorectal Cancer

(Markets Insider) Aug 7, 2018 - Array BioPharma Inc. today announced it has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for encorafenib (BRAFTOVI™), in combination with binimetinib (MEKTOVI®) and cetuximab for the treatment of patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC) as detected by an FDA-approved test, after failure of one to two prior lines of therapy for metastatic disease. BRAFV600E-mutant mCRC patients have a mortality risk more than double that of mCRC patients without the mutation, and currently there are no therapies specifically approved for this high unmet need population. Breakthrough Therapy Designation is an FDA process designed to expedite the development and review of drugs that are intended to treat a serious condition where preliminary clinical evidence indicates that they may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints.

read article

3 New Projects Map Out Immune Responses To Cancers

(Fred Hutch News Service) July 30, 2018 - The immune system has the potential to eradicate cancer. But cancers are expert escape artists, with numerous tools for shutting down or hiding from immune attack. Three research teams at Fred Hutchinson Cancer Research Center have launched new projects aimed at revealing some of these secrets and laying the groundwork for developing better immune-harnessing cancer therapies, or immunotherapies.

read article

Adherence to Healthy Diets Associated with Lower Cancer Risk

(AACR) July 26, 2018 - A diet that encourages both healthy eating and physical activity and discourages alcohol consumption was associated with a reduced overall cancer risk, as well as lower breast, prostate, and colorectal cancer risks, according to an analysis published in Cancer Research, a journal of the American Association for Cancer Research.

read press release

Patients with Right-Sided Colon Cancer Have Poorer Survival Rates than Those with Left-Sided Disease

(FACS) July 23, 2018 - Patients with colorectal cancer tumors on the right side may have poorer five-year survival rates than those whose tumors are located on the left side. However, a new large-scale retrospective study is the first to demonstrate a potential improvement of these outcomes. Study results show that nearly doubling the benchmark number of lymph nodes removed during operations for right-sided colon cancers improves the survival rate for these patients, according to researchers who presented these findings at the 2018 American College of Surgeons (ACS) Quality and Safety Conference.

read press release

Celyad Announces FDA Acceptance of IND Application for CYAD-101, a First-in-Class Non-Gene Edited Allogeneic CAR-T Candidate

(Celyad) July 24, 2018 - Celyad, a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug (IND) application for CYAD-101, the first non-gene edited allogeneic clinical program.

read corporate press release

Biocept and UC San Diego Moores Cancer Center Announce Collaboration to Study Feasibility of Liquid Biopsy to Predict Disease Recurrence in Solid Tumors and Response to Therapy

(Morningstar) July 23, 2018 - Biocept, Inc., a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it will work with Moores Cancer Center at UC San Diego Health to conduct two clinical studies in patients with a variety of solid tumors.

read article
Next Page